Tyrosine News and Research

RSS

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

21 Apr 2021

Screening drug candidates for COVID-19 treatment using computational methods

Researchers identified two potential drug candidates that can inhibit SARS-CoV-2 in vitro. Their combination can work synergistically and increase their inhibitory effect.

19 Apr 2021

Mirati to contribute $4 million grant to support SU2C research on KRAS mutant cancers

Stand Up To Cancer and Mirati Therapeutics Inc. - a late-stage targeted oncology company - today announced that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst program.

19 Apr 2021

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.

17 Apr 2021

Zipper motif mediates SARS-CoV-2 spike trimerization within host cell membrane

A new preprint research paper posted to the bioRxiv* server describes the results of a nuclear magnetic resonance (NMR) study to determine the structure of the S protein transmembrane domain (TMD) and its membrane-proximal regions.

13 Apr 2021

SARS-CoV-2 spike E484K mutation reduces antibody neutralization

Researchers at the Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, USA, showed that the SARS-CoV-2 spike E484K mutation reduces antibody neutralization.

12 Apr 2021

Development of a model of substrate coordination to Zn-bound ACE2

The ongoing coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has claimed more than 2.8 million lives worldwide. Authorities are facing difficulty in preventing the spread of disease due to the highly infectious nature of SARS-CoV-2. Therefore, reducing the virus's ability to infect an individual's respiratory epithelial cells could prove an effective measure to prevent disease transmission.

31 Mar 2021

Speakers Announced for Virtual Experimental Biology 2021 Meeting

Renowned scientists—including Nobel laureates, research pioneers, and celebrated educators—will speak at the virtual Experimental Biology (EB) 2021 meeting, to be held April 27–30.

23 Mar 2021

Immuno-PET detects changes in different cancer receptors in response to targeted therapies

Immuno-positron emission tomography (PET) imaging can provide early insight into a tumor's response to targeted therapy, allowing physicians to select the most effective treatment for patients who have cancer.

13 Mar 2021

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

Researchers at the University of Texas, USA, have confirmed the specific mutation in the B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has allowed for it to be more transmissible than the ancestral strain. The N501Y substitution is one of 8 spike protein substitutions present in the UK variant and has also appeared convergently in the Brazil (P.1) and South Africa (B.1.351) variants.

11 Mar 2021

Studies reveal how kidney tumors' microenvironments change in response to immunotherapy

In the last two decades, immunotherapy has emerged as a leading treatment for advanced renal carcinoma cancer (more commonly known as kidney cancer).

11 Mar 2021

Could an “ACE2 Triple Decoy” be an alternative approach to neutralizing SARS-CoV-2?

A team of scientists from the USA recently developed a recombinant “Angiotensin converting enzyme 2 (ACE2) Triple Decoy” that can trap SARS-CoV-2 and prevent its propagation inside the host cell.

11 Mar 2021

NTU scientists design new compound that could help reduce overactive immune response

When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.

10 Mar 2021

Researchers study prevalence of SARS-CoV-2 UK variant at University of Texas

Researchers at the University of Texas at Austin and Santa Fe Institute in the US used quantitative polymerase chain reaction (PCR) data from a surveillance testing program on a large university campus to estimate how fast the new variant spreads. The team used the data to provide local situational information on the COVID-19 pandemic.

10 Mar 2021

New compound can reduce overactivation without impairing the body's immunity response

10 Mar 2021

Researchers explore how N501Y mutation in SARS-CoV-2 increases viral transmissibility

Researchers at Erasmus University Medical Center in The Netherlands have explored how and why new variants of SARS-CoV-2 have exhibited heightened infectivity.

24 Feb 2021

New insights on structural biology may help design more efficient antibodies

In structural biology, some molecules are so unusual they can only be captured with a unique set of tools.

18 Feb 2021

Researchers unlock mysteries of protein that plays key regulatory role in cancer therapies

Researchers from the University of Virginia, Lehigh University, and the Massachusetts Institute of Technology are pooling their respective labs' expertise to unlock the mysteries of a protein that plays a critical regulatory role in human health and disease. Knowing how the protein works could lead to improved therapies for cancers and other diseases.

5 Feb 2021

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Among these is the B.1.1.7 SARS-CoV-2 variant, with its characteristic N501Y mutation. A new preprint on the bioRxiv server reports the impact of this mutation on CD4 T cell responses, including antigen presentation on cells expressing Major Histocompatibility Complex (MHC) class II molecules.

4 Feb 2021

Study discovers promising therapeutic agent to inhibit melanoma progression

There have been great advances in treating melanoma over the past five years, however, even with these treatments many patients quickly develop drug resistance and die from their disease.

1 Feb 2021

Tyrosine News and Research

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

Screening drug candidates for COVID-19 treatment using computational methods

Mirati to contribute $4 million grant to support SU2C research on KRAS mutant cancers

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Zipper motif mediates SARS-CoV-2 spike trimerization within host cell membrane

SARS-CoV-2 spike E484K mutation reduces antibody neutralization

Development of a model of substrate coordination to Zn-bound ACE2

Speakers Announced for Virtual Experimental Biology 2021 Meeting

Immuno-PET detects changes in different cancer receptors in response to targeted therapies

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

Studies reveal how kidney tumors' microenvironments change in response to immunotherapy

Could an “ACE2 Triple Decoy” be an alternative approach to neutralizing SARS-CoV-2?

NTU scientists design new compound that could help reduce overactive immune response

Researchers study prevalence of SARS-CoV-2 UK variant at University of Texas

New compound can reduce overactivation without impairing the body's immunity response

Researchers explore how N501Y mutation in SARS-CoV-2 increases viral transmissibility

New insights on structural biology may help design more efficient antibodies

Researchers unlock mysteries of protein that plays key regulatory role in cancer therapies

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Study discovers promising therapeutic agent to inhibit melanoma progression

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News